To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

December 14, 2018

Today's Rundown

Featured Story

Axovant buys more gene therapies, setting it up for a busy 2019

Axovant has licensed two gene therapies from the University of Massachusetts Medical School. The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.

Top Stories

Bellicum reports first data on ‘controllable’ CAR-T

Bellicum Pharma has the first data on BPX-601, its first CAR-T with a built-in activation switch to boost its effects, and says initial results show signs of biologic activity.

Mission Bio reels in $30M for single-cell genomics tech for oncology, CRISPR

Since launching at the end of 2017 with a focus on blood cancers, Mission Bio has built out its single-cell genomics platform to include custom offerings. Now, the company is raising $30 million to expand its reach into solid tumors and CRISPR applications.

[Sponsored] Mining Real-World Data With Cutting-Edge Analytical Tools

In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream.

Idera’s TLR9-Yervoy combo sees ‘impressive’ disease control in PD-1-refractory melanoma

On top of positive phase 1 results suggesting its TLR9 agonist tilsotolimod could work in synergy with CTLA4 inhibitor Yervoy, Idera has returned with phase 2 data that shows a 76.5% disease control rate for the combination.

Sensorion’s vertigo drug hits tolerability endpoint in phase 2

A phase 2a trial of Sensorion’s vertigo drug seliforant has met its primary tolerability endpoint. The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance, suggesting it may have an edge over existing vertigo treatments such as meclizine.

Eli Lilly and Evidation expand digital biomarker collaboration to data from smartphones and wearables

Eli Lilly & Co. is expanding its collaboration with Evidation Health into a multiyear project aimed at developing digital biomarkers for disease, derived from smartphones, wearable sensors and even voice data.

EuroBiotech Report—Lilly-AC Immune, AstraZeneca, Circassia, Novo and Biofrontera

In this week's EuroBiotech Report, AC Immune lands Lilly deal, AstraZeneca’s tremelimumab fails again and Novo inks diabetes deal.

FiercePharmaAsia—Possible Sun probe; Huahai warning letter; Eisai-UCL neuro pact

India’s securities regulators say they're examining whistleblower allegations against Sun; the Chinese API maker at the heart of a global recall of valsartan gets an FDA warning letter; Eisai and University College London push the first candidate in their neuro pact into the clinic; and more.

Chutes & Ladders—Gilead swipes Roche pharma chief for CEO post

Gilead swipes Roche pharma chief for CEO post; Merck promotes oncology, vaccine executives to replace outgoing global health president; and Gritstone ramps up bispecifics with new antibody therapeutics chief. Those moves plus more hirings, firings and retirings throughout the industry.

Resources

[eBook] Digital Workflows: How to Focus Investment to Cut Costs and Drive Growth

Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin?

[Whitepaper] Evaluating RIM Suites? Unification matters.

Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more.

[Whitepaper] In-House Versus Outsource: A Decision-Making Guide

Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success.

[Webinar] Becton Dickinson’s Digital P2P Solution Simplifies Spend Management

Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization.

[Whitepaper] Evaluation of the claraT Total mRNA report in an RNA- Sequencing dataset from malignant melanoma cancer patients treated with Ipilimumab

Download the whitepaper to learn more.

[Whitepaper] Putting the Researcher in the Driver’s Seat

Learn how to fast-track your research workflows!

[Report] Clinical Operations Report: Learn the Top Industrywide Priorities

Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes.

[Webinar] QSP Approaches to Determine Best in Class Properties for Targeted Anabolic Growth Factor to Arthritic Joints

This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints.

[Research Report] Challenges And Opportunities In Clinical Data Management

New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data.

[Whitepaper] Migraine Treatment and Calcitonin Gene-Related Peptide Inhibitors: Real-World EHR Case Study

New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management

[Whitepaper] The Future of Cell & Gene Therapy

What does data tell us about the future of cell & gene therapy?

[Whitepaper] Why Life Sciences Companies Leverage Managed Regulated Infrastructures

Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events